FDA approves first generic Climara Pro menopause patch, made by Zydus
By Vikram JoshiLife Balance Correspondent, Peepals Shakti
Representative image: erwinbosman / Pixabay
The US FDA approved Zydus's generic Climara Pro on October 20, 2026, the first generic of the weekly hormone patch for menopause symptoms and bone loss.
What Happened
The US Food and Drug Administration (FDA) on Tuesday, October 20, 2026, approved the first generic version of Climara Pro, a once-a-week skin patch that combines two hormones, estradiol and levonorgestrel, to treat moderate to severe hot flashes and night sweats caused by menopause and to help prevent bone loss after menopause. The generic patch is made by Zydus Pharmaceuticals (USA) Inc., the US arm of the Indian drugmaker Zydus. The FDA said the generic is therapeutically equivalent to the branded product, which is sold by Bayer. Launch date and price have not been announced.
Key Facts
- Approval: announced by the FDA on October 20, 2026.
- Product: a weekly transdermal (through-the-skin) patch releasing estradiol 0.045 mg a day and levonorgestrel 0.015 mg a day.
- Uses approved: moderate to severe vasomotor symptoms of menopause (hot flashes and night sweats) and prevention of postmenopausal osteoporosis.
- Who it is for: only women who still have a uterus; the progestogen part, levonorgestrel, protects the lining of the uterus from overgrowth caused by estrogen alone.
- Maker: Zydus Pharmaceuticals (USA) Inc.
- The approval was granted as a "competitive generic therapy", which makes the product eligible for 180 days of market exclusivity among generics, according to an industry publication.
- Launch timing, pricing and distribution have not been disclosed.
Why It Matters
Menopause is a normal stage of life, but for many women its symptoms are not minor. Hot flashes and night sweats can disrupt sleep for months or years, and poor sleep affects concentration, mood and work. The years around menopause also bring faster bone loss, which raises the risk of fractures later. These issues arrive at an age when many women are at the peak of their careers or carrying heavy family responsibilities, which is why menopause has become a workplace and wellbeing issue as much as a medical one.
Hormone therapy is one of the treatments doctors consider for these symptoms, but it is not right for everyone and carries risks that must be weighed individually. A patch is one way of delivering it: the hormones pass through the skin instead of being swallowed as a pill, and it is changed once a week. Combination products like this one, which pair an estrogen with a progestogen, are used in women who have a uterus.
The practical significance of a first generic is cost and access. When a generic enters the market, prices usually come down over time, which can make a treatment affordable for more people. In this case the price has not been announced, and the 180-day exclusivity means other generic makers may have to wait before they can compete. The approval applies to the United States; it does not by itself make the product available in India.
For Indian readers there is a second angle. The approval adds to the list of women's health products that Indian pharmaceutical companies make for the US market. It also comes amid a wider push, including in India, to talk more openly about menopause at work and in families.
| Item | Detail |
|---|---|
| Approved by | US Food and Drug Administration |
| Date | October 20, 2026 |
| Branded product | Climara Pro (Bayer) |
| Generic maker | Zydus Pharmaceuticals (USA) Inc. |
| Dose per day | Estradiol 0.045 mg, levonorgestrel 0.015 mg |
| Price and launch | Not announced |
Impact
Short-term: Nothing changes for patients until the generic launches; when it does, US patients and insurers will have a lower-cost alternative to the branded patch.
Long-term: Wider generic competition after the exclusivity period could further lower prices of combination hormone patches in the US.
Who is affected: Women in the US with menopausal symptoms who have a uterus, their doctors and insurers, and the makers of the branded and generic patches, including Zydus.
Key Takeaway
The FDA approved Zydus's generic Climara Pro hormone patch on October 20, 2026, the first generic of this weekly menopause treatment, though its price and launch date are not yet known.
Questions and Answers
What did the FDA approve for menopause in October 2026?
On October 20, 2026, the FDA approved the first generic of Climara Pro, a weekly estradiol and levonorgestrel patch for hot flashes, night sweats and prevention of bone loss after menopause.
Who makes the generic Climara Pro patch?
Zydus Pharmaceuticals (USA) Inc., the US arm of Indian drugmaker Zydus.
Can any woman use this patch?
No. It is approved only for women who still have a uterus, and whether hormone therapy is suitable is a decision for a woman and her doctor.
Is the generic patch available in India?
The approval applies only in the United States. Its US launch date and price have not been announced.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
By Vikram Joshi, Life Balance CorrespondentCovers Life Balance and more for Peepals Shakti. All stories by Vikram Joshi
Postpartum period may be a recovery window for maternal ageing, review proposes
Shein to pay $100 million to settle US FTC delivery complaints probe
Vikram Joshi is a pen name of the Peepals Global Editorial Team, which researches, fact-checks and publishes every story. The portrait is an illustration.
